One-year mortality in COVID-19 is associated with patients’ comorbidities rather than pneumonia severity

Novelli, Luca; Raimondi, Federico; Carioli, Greta; Carobbio, Alessandra; Pappacena, S; Biza, Roberta; Trapasso, Roberta; Anelli, Marisa; Amoroso, Mariangela; Allegri, Chiara; Malandrino, L; Imeri, Gianluca; Conti, Caterina; Beretta, Marta; Gori, Mauro; D’Elia, Emilia; Senni, Michele; Lorini, Ferdinando Luca; Rizzi, Marco; Cosentini, Roberto; Masciulli, Arianna; Gavazzi, Antonello; Solidoro, Paolo; Sironi, Sandro; Fagiuoli, Stefano; Barbui, Tiziano; Marco, Fabiano Di

doi:10.1016/j.resmer.2022.100976

Cited by 16 publications

(26 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Differences in our PFT findings from other studies may be due to the variation pulmonary function reference ranges used, PFT lab variability, SARS-CoV-2 variants involved (both observational studies included cohorts enrolled pre delta wave), pre-existing comorbidities of subjects or differences in COVID-19 management at the respective places and times. The 1-year mortality in our study was comparable to others as we found a 38% 1-year mortality in our placebo group compared to 30-50% seen in other studies assessing those hospitalized for COVID-19 38,39 .…”

Section: Discussionsupporting

confidence: 88%

Pulmonary function and survival one year after dupilumab treatment of acute moderate to severe COVID-19: A follow up study from a Phase IIa trial

Hendrick,

Ma,

Haughey

et al. 2023

Preprint

View full text Add to dashboard Cite

BackgroundWe previously conducted a Phase IIa randomized placebo-controlled trial of 40 subjects to assess the efficacy and safety of dupilumab use in those hospitalized with COVID-19 (NCT04920916). Based on our pre-clinical data suggesting downstream pulmonary dysfunction with COVID-19 induced type 2 inflammation, we contacted patients from our Phase IIa study at 1 year for assessment of Post Covid-19 Conditions (PCC).MethodsSubjects at 1 year after treatment underwent pulmonary function testing (PFTs), high resolution computed tomography (HRCT) imaging, symptom questionnaires, neurocognitive assessments, and serum immune biomarker analysis, with subject survival also monitored. The primary outcome was the proportion of abnormal PFTs, defined as an abnormal diffusion capacity for carbon monoxide (DLCO) or 6-minute walk testing (6MWT) at the 1-year visit.ResultsSixteen of the 29 one-year survivors consented to the follow up visit. We found that subjects who had originally received dupilumab were less likely to have abnormal PFTs compared to those who received placebo (Fisher’s exact p=0.011, adjusted p=0.058). We additionally found that 3 out of 19 subjects (16%) in the dupilumab group died by 1 year compared to 8 out of 21 subjects (38%) in the placebo group (log rank p=0.12). We did not find significant differences in neurocognitive testing, symptoms or CT chest imaging between treatment groups but observed evidence of reduced type 2 inflammation in those who received dupilumab.ConclusionsWe observed evidence of reduced long-term morbidity and mortality from COVID-19 with dupilumab treatment during acute hospitalization when added to standard of care regimens.

show abstract

Section: Discussionsupporting

confidence: 88%

Pulmonary function and survival one year after dupilumab treatment of acute moderate to severe COVID-19: A follow up study from a Phase IIa trial

Hendrick,

Ma,

Haughey

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…In the study of Novelli et al ., the 1-year mortality rate after discharge was found to be 3.7%. [ 20 ] Similarly, Ramzi’s systematic review and meta-analysis focusing specifically on postdischarge all-cause mortality rates have reported the overall 1-year mortality rate as 7.5%. [ 21 ]…”

Section: Discussionmentioning

confidence: 99%

Relationship of right ventricular functions with in-hospital and 1 year later mortality in patients hospitalized for COVID-19 pneumonia

Askar,

Karaduman,

Coldur

et al. 2024

Annals of Thoracic Medicine

View full text Add to dashboard Cite

BACKGROUND: The aim of this study was to determine the association of right ventricular function with in-hospital mortality and mortality 1 year after discharge in patients hospitalized for COVID-19 pneumonia. METHODS: The study was conducted in Van Yuzuncu Yil University Faculty of Medicine hospital between February 10, 2021 and August 10, 2022. A total of 156 patients hospitalized in intensive care and wards due to COVID-19 pneumonia were included in this study. Echocardiography was performed in all patients. RESULTS: Among the demographic findings of the patients included in the study, male gender, patients hospitalized in the intensive care unit (ICU), patients receiving O2 support, and smokers were found to have higher mortality rates during hospitalization. At the end of 1 year, the mortality rate was higher in patients who were hospitalized in the ICU received O2 support and had diabetes mellitus. Among echocardiographic findings, those with a low left ventricular ejection fraction had higher early and 1-year mortality rates. Of the right ventricular functions, low fractional area change, high systolic pulmonary artery pressure (SPAP), shortened pulmonary acceleration time, low right ventricle systolic wave S’ velocity, increased right atrium area, and inferior vena cava diameter were found to be associated with high mortality. Increased right atrial area and inferior vena cava diameter, increased SPAP, and shortened pulmonary acceleration time were found to be significant in 1-year mortality. The presence of pericardial effusion was associated with mortality during hospitalization but not with 1-year mortality. B-type natriuretic peptide, D-dimer, and hemoglobin levels were significantly correlated with both hospital mortality and 1-year mortality. CONCLUSIONS: In the follow-up of COVID-19 pneumonia, right ventricular function is considered to be an important factor in early and late mortality. It could be helpful to establish a follow-up program for discharged patients from the parameters involved in mortality.

show abstract

“…9,10 Pneumonia or respiratory failure are common complications in COVID-19 cases and can be deadly. [11][12][13][14] The chance of developing a severe disease from COVID-19 can rise with age and certain preexisting medical conditions. Comorbidities like hypertension, obesity, diabetes, and smoking are very common in Mexico, which raises the risk of COVID-19.…”

Section: Introductionmentioning

confidence: 99%

“…The severity of the disease is modulated by coexisting medical disorders 9,10 . Pneumonia or respiratory failure are common complications in COVID‐19 cases and can be deadly 11‐14 …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Hospitalized COVID‐19 patients with diabetes have an increased risk for pneumonia, intensive care unit requirement, intubation, and death: A cross‐sectional cohort study in Mexico in 2020

Huang

2023

Health Science Reports

View full text Add to dashboard Cite

Background: Diabetes mellitus is a chronic health condition that has been linked with an increased risk of severe illness and mortality from COVID-19. In Mexico, the impact of diabetes on COVID-19 outcomes in hospitalized patients has not been fully quantified. Understanding the increased risk posed by diabetes in this patient population can help healthcare providers better allocate resources and improve patient outcomes. Objective: The objective of this study was to quantify the extent outcomes (pneumonia, intensive care unit [ICU] stay, intubation, and death) are worsened in diabetic patients with COVID-19. Methods: Between April 14, 2020 and December 20, 2020 (last accessed), data from the open-source COVID-19 database maintained by the Mexican Federal Government were examined. Utilizing hospitalized COVID-19 patients with complete outcome data, a retrospective cohort study (N = 402,388) was carried out. In relation to COVID-19, both univariate and multivariate logistic regression were used to investigate the effect of diabetes on specific outcomes. Results: The analysis included 402,388 adults (age >18) with confirmed hospitalized COVID-19 cases with mean age 46.16 (standard deviation = 15.55), 214,161 (53%) male. The outcomes delineated included pneumonia (N = 88,064; 22%), ICU

show abstract

One-year mortality in COVID-19 is associated with patients’ comorbidities rather than pneumonia severity

Cited by 16 publications

References 27 publications

Pulmonary function and survival one year after dupilumab treatment of acute moderate to severe COVID-19: A follow up study from a Phase IIa trial

Pulmonary function and survival one year after dupilumab treatment of acute moderate to severe COVID-19: A follow up study from a Phase IIa trial

Relationship of right ventricular functions with in-hospital and 1 year later mortality in patients hospitalized for COVID-19 pneumonia

Hospitalized COVID‐19 patients with diabetes have an increased risk for pneumonia, intensive care unit requirement, intubation, and death: A cross‐sectional cohort study in Mexico in 2020

Contact Info

Product

Resources

About